Speciality Medicines IPO Details
Speciality Medicines IPO Summary
Speciality Medicines IPO opens for subscription on 20 Mar 2026 and closes on 24 Mar 2026.The IPO will be listed on BSE with the tentative listing date set for 30 Mar 2026.
Speciality Medicines IPO price band has been fixed at ₹117 – ₹124 per share. The face value is ₹10 per share with a lot size of 1000.
Speciality Medicines IPO total issue size comprises 23,50,000 shares (aggregating up to ₹29.14 Cr). This includes a fresh issue of 23,50,000 shares (aggregating up to ₹29.14 Cr). Pre-issue shareholding stands at 64,35,796, which will increase to 87,85,796 post-issue.
Speciality Medicines IPO carries a ₹0 (0%) GMP, reflecting investor sentiment.
Speciality Medicines IPO Lot Size :Individual Minimum is 2 lots (2,000 shares) amounting to ₹248,000. Individual Maximum is 2 lots (2,000 shares) amounting to ₹248,000. SHNI Minimum is 3 lots (3,000 shares) amounting to ₹372,000. SHNI Maximum is 8 lots (8,000 shares) amounting to ₹992,000. BHNI Minimum is 9 lots (9,000 shares) amounting to ₹1,116,000.
Speciality Medicines IPO Details
Speciality Medicines IPO Subscription
Speciality Medicines IPO Application Wise Breakup
Speciality Medicines IPO Dates
- 20 Mar 2026Opening dateOpen
- 24 Mar 2026Closing dateClose
- 25 Mar 2026Allotment Date Allotment
- 27 Mar 2026Initiation of RefundsRefund
- 27 Mar 2026Credit of SharesCredit
- 30 Mar 2026Listing dateListing
Speciality Medicines IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual Minimum | 2 | 2000 | ₹248,000 |
| Individual Maximum | 2 | 2000 | ₹248,000 |
| SHNI Minimum | 3 | 3000 | ₹372,000 |
| SHNI Maximum | 8 | 8000 | ₹992,000 |
| BHNI Minimum | 9 | 9000 | ₹1,116,000 |
Speciality Medicines IPO Reservation
Promoter Holding
Documents
Speciality Medicines IPO Valuations
Speciality Medicines Financial Information
| Period Ended | 31 Oct 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 45.57 | 39.98 | 22.68 |
| Total Income | 36.93 | 58.54 | 27.66 |
| Profit After Tax | 6.06 | 8.61 | 2.93 |
| EBITDA | 6.51 | 9.09 | 5.26 |
| NET Worth | 36.47 | 30.42 | 15.06 |
| Reserves and Surplus | 30.04 | 23.98 | 9.95 |
| Total Borrowing | 4.81 | 5.05 | 2.86 |
| Amount in ₹ Crore | |||
About Speciality Medicines IPO
Speciality Medicines Limited, incorporated in 2021, is engaged in the marketing and distribution of finished formulations of specialty pharmaceuticals, including high-value oral and injectable medications used in the treatment of complex chronic conditions. The company operates across both domestic and international markets.
The company offers a diverse portfolio of specialty pharmaceutical products available in multiple dosage forms such as tablets, capsules, creams, syrups, eye drops, gels, infusions, inhalers, injections, nasal sprays, ointments, ophthalmic solutions, oral solutions, sachets, and suspensions.
Speciality Medicines Limited operates through two primary business models:
Contract Manufacturing: The company undertakes contract manufacturing of finished pharmaceutical formulations for international markets, catering to specific regulatory and customer requirements.
Marketing and Distribution: The company markets and distributes sourced specialty pharmaceutical products across its domestic and global distribution network.
The company has established an international presence with registered or pending pharmaceutical products in countries such as Jordan, Ethiopia, Uganda, Peru, and Namibia. It has built a strong distribution network with relationships across more than 20 states in India and over 35 countries globally.
As of March 31, 2025, the company had one product registered in international markets and approximately 60 products under the registration process across five countries, contributing to its revenue growth strategy.
As of August 31, 2025, Speciality Medicines Limited had a total workforce of 18 permanent employees.
Strength Of Speciality Medicines IPO
- A Supplier of Specialty pharmaceuticals.
- Experienced Promoters and Management Team.
- Diversified Business Operations and Revenue Base.
- Scalable Business Model.
- Quality Assurance.
- Existing Client Relationship.
- Well Established Systems and Procedures.
Risk Of Speciality Medicines IPO
- The company has certain outstanding litigation against it, an adverse outcome of which may adversely affect its business, reputation and results of operations.
- The company is subject to strict technical specifications, quality requirements by its customers. The company failures to comply with the quality standards and technical specifications prescribed by such customers may lead to loss of business from such customers and could negatively impact its business, results of warranty claims.
- The pharmaceutical market is subject to extensive regulation and failures to comply with the existing and future regulatory requirements in any pharmaceutical market could expose it to litigation or other liabilities, which could adversely affect its reputation, business, financial condition and results of operations.
- The company limited operating history may make it challenging for investors to assess its future growth prospects and overall business performance since the company was incorporated on February 05, 2021, which makes it a relatively new entity with a short track record of business and financial activities.
- The company business is working capital intensive. If its unable to borrow to meet the company working capital requirements, it may materially and adversely affect its business and results of operations.
- The company has not yet placed orders in relation to the funding Capital Expenditure towards establishment of Research and Development (R&D) Center comprising Construction of Building and Lab equipment which is proposed to be financed from the Issue proceeds of the IPO. In the event of any delay in placing the orders, or in the event the vendors are not able to provide the building and equipment in a timely manner, or at all, may result in time and cost over-runs and its business, prospects and results of operations may be adversely affected. Its proposed Research and Development (R&D) Center plans are subject to the risk of unanticipated delays in implementation due to factors including delays in construction, obtaining regulatory approvals in timely manner and cost overruns.
- Delay in registration of Products in multiple geographical locations across the world may affect its revenue generation and overall financial performance.
- The company requires a number of approvals, licences, registrations and permits in the ordinary course of its business and any failures or delay in obtaining the same in a timely manner may adversely affect the company operations.
- The products that the company commercialize may not perform as expected which could adversely affect its business, financial condition and results of operations.
- The Company does not have any experience in Research and Development Activities and will be depending on professional staff to be appointed by the Company.
Objectives Speciality Medicines IPO
1. Setting up of Research and Development (R&D) Center
2. Product registration in the international markets
3. Repayment/ Prepayment, in full or part, of certain borrowings availed by the Company
4. To Meet Working Capital Requirements
5. General Corporate Purpose
Company Contact Details
Speciality Medicines Ltd.
913, One World West, S. No. 396, FP 119,
Village- Vejalpur, Ahmadabad City,
Ahmedabad, Gujarat, India,
Ahmedabad, Gujarat, 380051
Phone: +91 22 4604 5344
Email: investors.grievances@specialitymedicine.com
Website: http://www.specialitymedicine.com/
Registrar Contact Details
Speciality Medicines FAQs
The Speciality Medicines IPO is a SME public issue comprising 2350000 equity shares with a face value of ₹10 each, aggregating to a total issue size of ₹29.14 Cr. The issue price has been fixed at ₹124 per equity share, and the minimum application size is 1000 shares.
The IPO opens for subscription on 20 Mar 2026, and closes on 24 Mar 2026.
Skyline Financial Services Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the BSE
As of now, the current GMP stands at ₹0 (0%).
Quick Links
Comments
